Top

World Journal of Surgery

Published in:

01-07-2017 | Original Scientific Report

Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma

Authors: Kun Woo Kim, Hong Kwan Kim, Jhingook Kim, Young Mog Shim, Myung-Ju Ahn, Yoon-La Choi

Published in: World Journal of Surgery | Issue 7/2017

Abstract

Background

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is pathologically classified as non-small-cell lung cancer (NSCLC), but its clinical behavior is more aggressive than other types of NSCLC. Accordingly, the optimal treatment strategy for LCNEC, including the indication of adjuvant treatment, remains controversial.

Methods

A retrospective review of 139 patients who underwent curative-intent surgery for LCNEC was performed to investigate clinicopathologic features and survival outcomes and to evaluate whether adjuvant treatment affected survival outcomes.

Results

The mean patient age was 64 years (126 men, 90.6%). Operative procedures included 111 lobectomies (79.8%), 12 pneumonectomies (8.6%), and 2 sublobar resections. Pathologic stage was IA in 31 (22%), IB in 36 (26%), IIA in 34 (24%), IIB in 9 (6%), IIIA in 19 (14%), IIIB in 2 (1.4%), and IV in 4 patients (2.9%). Postoperatively, 50 patients (36%) received adjuvant treatment. The median follow-up duration was 33 months. The 5-year overall survival (OS) rate was 53%, and 5-year disease-free survival (DFS) rate was 39%. In patients with pathologic stage I, there was no significant difference in either OS or DFS according to the addition of adjuvant treatment. However, in patients with pathologic stage II or higher, patients who underwent adjuvant treatment showed significantly better OS (p = 0.023) and DFS (p = 0.038).

Conclusions

Our findings showed that patients who underwent curative-intent surgery for LCNEC benefitted from the use of adjuvant treatment especially in pathologic stage II or higher.

Travis WD (2010) Advances in neuroendocrine lung tumors. Ann Oncol 7:65–71

Asamura H, Kameya T, MAtsuno Y et al (2006) Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24:70–76CrossRefPubMed

Fernandez FG, Battafarano RJ (2006) Large-cell neuroendocrine carcinoma of the lung. Cancer Control 13:270–275PubMed

Iyoda A, Jiang SX, Travis WD et al (2013) Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma. Mol Clin Oncol 1:437–443PubMedPubMedCentral

Gollard R, Jhatakia S, Elliott M et al (2010) Large cell/neuroendocrine carcinoma. Lung Cancer 69:13–18CrossRefPubMed

Battafarano RJ, Fernandez FG, Ritter J et al (2005) Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg 130:166–172CrossRefPubMed

Doddoli C, Barlesi F, Chetaille B et al (2004) Large cell neuroendocrine carcinoma of the lung: an aggressive disease potentially treatable with surgery. Ann Thorac Surg 77:1168–1172CrossRefPubMed

Iyoda A, Hiroshima K, Nakatani Y et al (2007) Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg 84:702–707CrossRefPubMed

Kumar P, Herndon J 2nd, Langer M et al (1996) Pattern of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer 77:2393–2399CrossRefPubMed

10.

Williams CD, Gajra A, Ganti AK et al (2014) Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. Cancer 120:1939–1947CrossRefPubMed

11.

Howington JA, Blum MG, Chang AC et al (2013) Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:278–313CrossRef

12.

Saji H, Tsuboi M, Matsubayashi J et al (2010) Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs 21:89–93CrossRefPubMed

13.

Sarkaria IS, Iyoda A, Roh MS et al (2011) Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinoma: a single institution experience. Ann Thorac Surg 92:1180–1186CrossRefPubMed

14.

Travis WD, Brambilla E, Müller-Hermelink HK et al (2004) Pathology and genetics: tumors of the lung, pleura, thymus and heart. IARC, Lyon

15.

Edge S, Byrd DR, Compton CC et al (2009) AJCC cancer staging manual, 7th edn. Springer, New York

16.

Paci M, Cavazza A, Annessi V et al (2004) Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study. Ann Thorac Surg 77:1163–1167CrossRefPubMed

17.

Veronesi G, Morandi U, Alloisio M et al (2006) Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer 53:111–115CrossRefPubMed

18.

Iyoda A, Hiroshima K, Moriya Y et al (2009) Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg 138:446–453CrossRefPubMed

19.

Iyoda A, Hiroshima K, Moriya Y et al (2006) Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non small cell carcinoma. J Thorac Cardiovasc Surg 132:312–315CrossRefPubMed

20.

Dresler CM, Ritter JH, Patterson GA et al (1997) Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 63:180–185CrossRefPubMed

21.

Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association[ANITA]): a randomized controlled trial. Lancet Oncol 7:719–727CrossRefPubMed

22.

Butts CA, Ding K, Seymour L et al (2010) Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 28:29–34CrossRefPubMed

23.

Ettinger DS, Akerley W, Borghaei H et al (2013) Non-small cell lung cancer, version2. 2013. J Natl Compr Canc Netw 11:645–653CrossRefPubMed

24.

Roesel C, Terjung S, Weinreich G et al (2016) A single-institution analysis of the surgical management of pulmonary large cell neuroendocrine carcinomas. Ann Thorac Surg 101:1909–1914CrossRef

Title: Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma
Authors: Kun Woo Kim
Hong Kwan Kim
Jhingook Kim
Young Mog Shim
Myung-Ju Ahn
Yoon-La Choi
Publication date: 01-07-2017
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 7/2017
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-017-3908-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2017

Surgical Treatment of Gastroesophageal Reflux Disease

Clinico-pathological Correlation of Thyroid Nodule Ultrasound and Cytology Using the TIRADS and Bethesda Classifications

Evaluation of Gastroesophageal Reflux Disease

Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis

From Heartburn to Barrett’s Esophagus, and Beyond

The Influence of Clinical and Patient-Reported Outcomes on Post-surgery Satisfaction in Cholecystectomy Patients